featured
Zanubrutinib vs Ibrutinib for Symptomatic Waldenström Macroglobulinemia
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study
J. Clin. Oncol 2023 Jul 21;[EPub Ahead of Print], MA Dimopoulos, S Opat, S D'Sa, W Jurczak, HP Lee, G Cull, RG Owen, P Marlton, BE Wahlin, R Garcia-Sanz, H McCarthy, S Mulligan, A Tedeschi, JJ Castillo, J Czyz, C Fernández de Larrea, D Belada, E Libby, J Matous, M Motta, T Siddiqi, M Tani, M Trněný, MC Minnema, C Buske, V Leblond, SP Treon, J Trotman, WY Chan, J Schneider, H Allewelt, S Patel, A Cohen, CS TamFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.